Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:collaboratesWith |
Local healthcare institutions
|
| gptkbp:contributedTo |
Healthcare_innovation_in_China
|
| gptkbp:employs |
Over 1,000 people
|
| gptkbp:engagesIn |
Clinical trials
|
| gptkbp:focusesOn |
Research_and_Development
|
| gptkbp:founded |
2002
|
| gptkbp:hasAwards |
Industry recognition
Quality awards Innovation awards |
| gptkbp:hasLocalCuisine |
Phase II
Phase III Post-marketing studies Phase I Real-world evidence studies |
| gptkbp:hasPartnershipsWith |
Academic institutions
Government agencies Biotech_companies |
| gptkbp:hasProductLine |
Diagnostics
Anticancer drugs Rheumatoid arthritis treatments |
| gptkbp:hasResearchInterest |
gptkb:Guangzhou
gptkb:Beijing gptkb:Shanghai |
| gptkbp:hasResidence |
Over $500 million
|
| gptkbp:headquarters |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharma China
|
| gptkbp:isActiveIn |
Immunology
Neuroscience Oncology Cardiovascular diseases Rare diseases |
| gptkbp:isInvolvedIn |
Health awareness campaigns
Sustainability efforts Research collaborations Community health programs Corporate social responsibility initiatives Patient education programs |
| gptkbp:isKnownFor |
Patient-centric approach
High-quality pharmaceuticals Strong pipeline of new drugs |
| gptkbp:isRegulatedBy |
gptkb:China_Food_and_Drug_Administration_(CFDA)
National_Medical_Products_Administration_(NMPA) |
| gptkbp:market |
Global market
Asia-Pacific_region |
| gptkbp:offers |
Biopharmaceuticals
|
| gptkbp:operatesIn |
gptkb:China
|
| gptkbp:partOf |
gptkb:Roche_Group
|
| gptkbp:subsidiary |
gptkb:Chugai_Pharmaceutical_Co.,_Ltd.
|